FDA approves secukinumab for adults with HS
The U.S. Food and Drug Administration (FDA) has approved secukinumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). This development, announced today, makes secukinumab the first and only interleukin (IL)-17A inhibitor approved by the FDA for the treatment of HS, which affects approximately 1% of the global population. It joins adalimumab, …